APH APH アンフェノ―ル

Amphenol Corporation with ticker code (APH) now have 14 analysts covering the stock with the consensus suggesting a rating of ''Buy''. The target price ranges between 82 and 65 calculating the mean target price we have 74.64. Now with the previous closing price of 70.03 this would indicate that there is a potential upside of 6.6%. The day 50 moving average is 68.68 and the 200 moving average now moves to 66.65. The company has a market capitalisation of $42,431m. You can visit the company''s website by visiting: /> [stock_market_widget type="chart" symbol="APH" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Amphenol Corporation, together with its subsidiaries, primarily designs, manufactures, and markets electrical, electronic, and fiber optic connectors in the United States, China, and internationally. It operates in two segments, Interconnect Products and Assemblies, and Cable Products and Solutions. The Interconnect Products and Assemblies segment offers connector and connector systems, including fiber optic, harsh environment, high-speed, and radio frequency interconnect products, as well as antennas; power interconnect products, busbars, and distribution systems; and other connectors.

This report studies the Data Bus Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Data Bus market segmented by company, region, type []

This report studies the Advanced Carbon Dioxide Sensors Market with many aspects of the industry such as market size, market status, market trends and forecast. The report also provides brief information on competitors and opportunities for specific growth with the key market drivers. Find the comprehensive analysis of the Advanced Carbon Dioxide Sensors market segmented []

Amphenol Corp. - Class A (APH) shares closed today at 1.4% below its 52 week high of $71.05, giving the company a market cap of $41B. The stock is currently up 8.0% year-to-date, up 39.0% over the past 12 months, and up 149.0% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 fell 0.4%. Trading Activity Trading volume this week was 22.8% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Information Technology industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -79.1% The company's stock price performance over the past 12 months lags the peer average by -48.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 925.8% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Amphenol Corp. - Class A (APH) shares closed today at 1.3% below its 52 week high of $71.05, giving the company a market cap of $41B. The stock is currently up 5.6% year-to-date, up 36.8% over the past 12 months, and up 143.8% over the past five years. This week, the Dow Jones Industrial Average fell 1.1%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 20.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Information Technology industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -84.1% The company's stock price performance over the past 12 months lags the peer average by -50.0% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 915.4% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Get Sample Report Buy Complete Report Request for Customization The report titled Global Press-Fit Connectors Market is carefully analyzed and researched about by the market analysts.The market analysts and researchers have done extensive analysis of the global Press-Fit Connectors market with the help of research methodologies such as PESTLE and Porters Five Forces analysis. []

Global Circular Connectors Market 2021 by Manufacturers, Regions, Type and Application, Forecast to 2026 prepared by Courant Market Research is a superior compilation of different types of analysis of critical aspects of the global market. The report joins the latest methodologies and new releases to interface with the clients to set up, settle on productive []

Up Market Research (UMR) published a latest research report on Contact Temperature Sensors Sales Market 2021. The Research Report is a comprehensive and in-depth analysis of the global Contact Temperature Sensors Sales Market. The report provides detailed information about current trends, drivers, and challenges facing this industry. This research not only helps companies take accurate []

Industry Growth Insights (IGI) published a latest research report on Backplane Connectors Market 2021. The Research Report is a comprehensive and in-depth analysis of the global Backplane Connectors Market. The report provides detailed information about current trends, drivers, and challenges facing this industry. This research not only helps companies take accurate business decisions; it also []

A market research report helps in gathering and analysing useful insights such as global market size, forecast and Compound Annual Growth Rate (CAGR) of a particular industry. It also helps in determining the market status, future prospects, growth opportunity, main challenges about the market for any industry. A market research report also provides complete analysis []

When Tilray Inc's (NASDAQ: TLRY ) formally merged with Aphria on May 3, it was a "sell the news" event. Tilray is trading down 14% from when the new Tilray was created and its stock has been stuck near a support and resistance level at $15.17 for the last 10 trading days. The Tilray Chart: On Thursday, Tilray popped back over the $15 area and was trading slightly above the eight-day exponential moving average (EMA). Tilray’s stock has the support of the 200-day simple moving average, which is trending slightly upwards indicating the overall sentiment in the stock is bullish. Tilray is trading below … Full story available on Benzinga.com

Summary List Placement Welcome to Insider Cannabis, our weekly newsletter where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar global cannabis boom. Sign up here to get it in your inbox every week . The biggest US cannabis companies — including Trulieve , Green Thumb Industries , and Curaleaf — reported strong earnings this week. But their stock prices still fell, for the most part. Why's that? "I think, quite frankly, nothing's new when it comes to US cannabis," Trulieve CEO Kim Rivers told me in an interview yesterday. "A good portion of that comes from the way our stocks are required to be listed." US cannabis company can't list on US exchanges because cannabis is federally illegal. Rivers says that without exposure to deeper-pocketed institutional investors on the NYSE or Nasdaq, the story will continue to be the same. It also didn't help that Wasatch , a Salt Lake City-based asset manager, was reportedly forced to unwind its positions in US cannabis names because of issues with compliance and finding a custodian. "I think there's certainly going to be a change in that dynamic once uplisting is allowed," Rivers said.

Summary List Placement Irwin Simon knows a thing or two about putting together deals. As the founder and CEO of Hain Celestial from 1993 to 2018, he pursued 55 acquisitions as he built up the health foods and supplements company, gaining a reputation on Wall Street as an expert dealmaker. After leaving Hain Celestial in 2018, Simon joined the board of Canadian cannabis company Aphria. He took over as CEO in March 2019, then helped engineer a merger with rival Canadian cannabis giant Tilray, which closed this month. In an interview with Insider, he said the difficulty of closing deals during his tenure at Hain Celestial paled in comparison to the $4 billion Tilray-Aphria mega-merger . Simon is now the CEO of the combined company, which retained the Tilray name. "Deals of this magnitude can easily fall apart," Simon said in an interview. "There were times I didn't think we would get it across the finish line." Tilray postponed a shareholder meeting to vote on the deal in April, and that led to some skepticism over whether it would actually close — especially in light of Aphria and the broader Canadian cannabis sector posting dismal quarterly earnings .

ENGLEWOOD, Colo. , May 10, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE: AMPE ), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today announced that it has received Investigational Review Board (IRB) approval to commence enrollment in its AP-018 Phase I study using inhaled Ampion™ with patients exhibiting prolonged respiratory COVID-19 symptoms, known as long (or long-haul) COVID, or Post-Acute Sequelae of SARS-CoV-2. "This trial is both needed and exciting in that it addresses a major current and expected ongoing unmet medical need among the estimated 3 to 10 million individuals currently suffering from long COVID ," said Michael Macaluso , President and CEO of Ampio. " A significant percentage of patients who have contracted COVID-19 over the past year – even those with mild or asymptomatic cases – continue to suffer debilitating effects long after there is no detectable virus in their system.

Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE ), a biopharma developing immunology-based therapies for inflammatory diseases, announced Monday it has received approval to initiate a clinical study of its lead asset for long COVID-19 treatment. Ampion's COVID-19 Study: Englewood, Colorado-based Ampio said an investigational review board has approved the initiation of a Phase 1 study, dubbed AP-018, of its inhaled Ampion in patients exhibiting prolonged respiratory COVID-19 symptoms. This condition is called long/long-haul COVID, or post-acute sequelae of SARS-CoV-2, the virus that causes COVID-19 disease. The Need For Long COVID-19 Treatment: With about 3 to 10 million individuals suffering from long COVID-19, this trial assumes importance … Full story available on Benzinga.com